X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
inhibidors enzimàtics (40) 40
enzyme inhibitors (37) 37
index medicus (23) 23
humans (18) 18
animals (10) 10
alzheimer's disease (8) 8
disseny de medicaments (8) 8
drug design (8) 8
enzyme inhibitors - pharmacology (8) 8
female (8) 8
male (8) 8
malaltia d'alzheimer (7) 7
protein kinases (7) 7
research article (7) 7
acetylcholinesterase (6) 6
cancer (6) 6
inhibitors (6) 6
medicine (6) 6
mice (6) 6
proteïnes quinases (6) 6
adult (5) 5
binding sites (5) 5
cell cycle (5) 5
càncer (5) 5
derivatives (5) 5
medicine, general & internal (5) 5
middle aged (5) 5
proteins (5) 5
structure-activity relationship (5) 5
abridged index medicus (4) 4
acetilcolinesterasa (4) 4
adolescent (4) 4
aged (4) 4
analysis (4) 4
antiretroviral agents (4) 4
antiretrovirals (4) 4
biology (4) 4
care and treatment (4) 4
chemistry, medicinal (4) 4
chemistry, organic (4) 4
chemotherapy (4) 4
drug therapy, combination (4) 4
enzyme inhibitors - chemistry (4) 4
kinases (4) 4
molecular structure (4) 4
organic synthesis (4) 4
physiological aspects (4) 4
protein (4) 4
research (4) 4
science (4) 4
síntesi orgànica (4) 4
usage (4) 4
alzheimers-disease (3) 3
amino acids (3) 3
antineoplastic agents - pharmacology (3) 3
apoptosis (3) 3
article (3) 3
children (3) 3
cholinesterase inhibitors - chemical synthesis (3) 3
cholinesterase inhibitors - chemistry (3) 3
cholinesterase inhibitors - pharmacology (3) 3
cyclin-dependent kinase inhibitor p27 - metabolism (3) 3
dose-response relationship, drug (3) 3
drugs (3) 3
enzyme inhibitors - administration & dosage (3) 3
epigenetics (3) 3
gene regulation, chromatin and epigenetics (3) 3
genetic engineering (3) 3
health aspects (3) 3
hematology (3) 3
hiv infections - drug therapy (3) 3
models, molecular (3) 3
multidisciplinary sciences (3) 3
neoplasms (3) 3
oncology (3) 3
oxidative stress (3) 3
protein binding (3) 3
rodents (3) 3
signal transduction (3) 3
torpedo-californica (3) 3
a beta aggregation inhibitors (2) 2
acetylcholinesterase - metabolism (2) 2
activation (2) 2
active-site (2) 2
aldehydes (2) 2
alpha-mannosidase (2) 2
aminoàcids (2) 2
amyloid beta-peptides - metabolism (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - chemistry (2) 2
antineoplastic agents - therapeutic use (2) 2
antiviral agents (2) 2
apoptosis - drug effects (2) 2
aβ aggregation inhibitors (2) 2
biochemistry (2) 2
biochemistry & molecular biology (2) 2
bioinformatics (2) 2
biological evaluation (2) 2
body weight (2) 2
breast (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1973 - 1982
In patients with HCV genotype 1 infection and cirrhosis, the rate of sustained virologic response was 92% with three new antiviral agents plus ribavirin for 12... 
SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | UNITED-STATES | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | TELAPREVIR | THERAPY | GENOTYPE 1 INFECTION | BOCEPREVIR | HCV INFECTION | EPIDEMIOLOGY | Recurrence | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Hepatitis C, Chronic - complications | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Logistic Models | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Complications and side effects | Evaluation | Care and treatment | Usage | Hepatitis C | Liver cirrhosis | Ribavirin | Headache | Antiviral agents | Ritonavir | Body weight | Fatigue | Infections | Nausea | Proteinase inhibitors | RNA polymerase | Patients | Cirrhosis | Liver cancer | Genotype & phenotype | Hepatitis | Hemoglobin | Interferon | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus | Cirrosi hepàtica | Inhibidors enzimàtics | Enzyme inhibitors | Hepatic cirrhosis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 10, pp. 917 - 927
Journal Article
ISSN 1554-8929, 11/2016
Important links exist between the process of pre-mRNA splicing and cancer, as illustrated by the frequent mutation of splicing factors in tumors and the... 
Inhibidors enzimàtics | Drugs | Medicaments | Càncer | Enzyme inhibitors | Cancer
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2016, Volume 22, Issue 18, pp. 4687 - 4697
Purpose: Triple-negative breast cancer (TNBC) lacks an approved targeted therapy. Despite initial good response to chemotherapy, 30% of the patients relapse... 
Inhibidors enzimàtics | Tractament | Càncer | Treatment | Enzyme inhibitors | Breast | Mama | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2007, Volume 357, Issue 25, pp. 2562 - 2575
This study examines the toxicity of immunosuppressive regimens in renal-transplant recipients. A regimen containing mycophenolate mofetil, daclizumab, low-dose... 
MULTICENTER TRIAL | MEDICINE, GENERAL & INTERNAL | CYCLOSPORINE MICROEMULSION | EFFICACY | KIDNEY-TRANSPLANTATION | IMMUNOSUPPRESSION | ALLOGRAFT RECIPIENTS | TACROLIMUS | MYCOPHENOLATE-MOFETIL | SIROLIMUS | NEPHROTOXICITY | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Adrenal Cortex Hormones - therapeutic use | Enzyme Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized | Calcineurin Inhibitors | Treatment Failure | Adult | Diabetes Mellitus - etiology | Female | Drug Therapy, Combination | Mycophenolic Acid - administration & dosage | Immunosuppressive Agents - administration & dosage | Sirolimus - adverse effects | Tacrolimus - administration & dosage | Prednisone - administration & dosage | Glomerular Filtration Rate | Graft Rejection - prevention & control | Kaplan-Meier Estimate | Kidney Transplantation | Immunoglobulin G - administration & dosage | Opportunistic Infections | Sirolimus - administration & dosage | Mycophenolic Acid - analogs & derivatives | Antibodies, Monoclonal - administration & dosage | Cyclosporine - administration & dosage | Immunosuppressive Agents - adverse effects | Aged | Adrenal Cortex Hormones - administration & dosage | Transplantation | Corticosteroids | Kidneys | Research | Health aspects | Immunosuppressive agents | Medical research | Immunology | Inhibitor drugs | Transplants & implants | Toxicity | Inhibidors enzimàtics | Posologia | Ús terapèutic | Corticosteroides | Rebuig (Biologia) | Posology | Therapeutic use | Immunosupressive agents | Graft rejection | Trasplantament renal | Enzyme inhibitors | Adrenocortical hormones | Immunosupressors | Kidney transplantation | Tacrolimus: administration & dosage | Medical and Health Sciences | Graft Rejection: prevention & control | Immunoglobulin G: administration & dosage | Medicin och hälsovetenskap | Mycophenolic Acid: administration & dosage | Antibodies | Klinisk medicin | Monoclonal: administration & dosage | Prednisone: administration & dosage | Adrenal Cortex Hormones: administration & dosage | Immunosuppressive Agents: administration & dosage | Mycophenolic Acid: analogs & derivatives | Sirolimus: administration & dosage | Cyclosporine: administration & dosage | Calcineurin: antagonists & inhibitors | Diabetes Mellitus: etiology | Urologi och njurmedicin | Sirolimus: adverse effects | Adrenal Cortex Hormones: therapeutic use | Enzyme Inhibitors: administration & dosage | Immunosuppressive Agents: adverse effects | Clinical Medicine | Immunosuppressive Agents: therapeutic use | Urology and Nephrology
Journal Article
ISSN 0025-7974, 03/2015
This is a cross-sectional study of 15 aviremic chronic HIV-infected children revealing no differences in immune activation (IA; HLA-DRCD38 CD4 and CD8 T cells,... 
Inhibidors enzimàtics | Antiretrovirals | HIV infections | Enzyme inhibitors | Antiretroviral agents | Infeccions per VIH | Infants | Children
Journal Article
ISSN 1949-2553, 11/2015
p27Kip1 (p27) is a negative regulator of proliferation and a tumor suppressor via the inhibition of cyclin-CDK activity in the nucleus. p27 is also involved in... 
Inhibidors enzimàtics | Proteïnes quinases | Enzyme inhibitors | Cicle cel·lular | Cell cycle | Pàncrees | Pancreas | Protein kinases
Journal Article
ISSN 0007-1145, 09/2011
In liver, through the reaction catalysed by alanine aminotransferase (ALT), alanine becomes an effective precursor for gluconeogenesis. In the present study... 
Inhibidors enzimàtics | Enzyme inhibitors | Sparus aurata | Orada | Aminoàcids | Amino acids
Journal Article
Journal of Organic Chemistry, ISSN 0022-3263, 02/2017, Volume 82, Issue 3, pp. 1851 - 1855
Treatment of readily available allene 1 with Cy2BH followed by addition of an aldehyde led to quaternary protected 2-amino-2-vinyl-1,3-diols in high yield and... 
SPHINGOLIPID METABOLISM | ROUTE | SPHINGOSINE-1-PHOSPHATE LYASE | SUBSTITUTED SERINES | CHEMISTRY, ORGANIC | ALPHA-AMINO-ACIDS | INHIBITORS | DERIVATIVES | Usage | Glycols | Chemical properties | Stereochemistry | Research | Isomerization | Inhibidors enzimàtics | Organic synthesis | Síntesi orgànica | Esfingolípids | Enzyme inhibitors | Sphingolipids | Aldehydes | Aldehids
Journal Article
Nucleic Acids Research, ISSN 0305-1048, 08/2012, Volume 40, Issue 14, pp. 6520 - 6533
P27(Kip1) (p27) is a member of the Cip/Kip family of cyclin-dependent kinase inhibitors. Recently, a new function of p27 as transcriptional regulator has been... 
Inhibidors enzimàtics | Proteïnes quinases | Enzyme inhibitors | Citologia | Protein kinases | Cytology | Gene Regulation, Chromatin and Epigenetics
Journal Article
Haematologica, ISSN 0390-6078, 01/2015, Volume 100, Issue 3, pp. 392 - 399
Journal Article
European Journal of Organic Chemistry, ISSN 1434-193X, 12/2017, Volume 2017, Issue 47, pp. 7179 - 7185
Journal Article